PTC Therapeutics, Inc. Class Action Lawsuit - PTCT

The filed complaint alleges that PTC Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients." Although "[t]he study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability", analysts who reviewed the data anticipated that the Company would likely need to conduct a Phase 3 study to better establish whether the treatment is actually slowing HD. Following this news, PTC's stock price fell over 18% on the same day.

In order to be eligible to join the PTCT class action lawsuit, you must have incurred a loss on shares of PTC Therapeutics, Inc. purchased during the class period listed above.